<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343445</url>
  </required_header>
  <id_info>
    <org_study_id>PS-G201</org_study_id>
    <nct_id>NCT02343445</nct_id>
  </id_info>
  <brief_title>Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)</brief_title>
  <acronym>CLEAN-CF</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of P-1037 Solution for Inhalation in Patients With Cystic Fibrosis (CF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parion Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Parion Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to evaluate the safety and tolerability of P-1037 and to determine
      whether the combination of P-1037 with hypertonic saline or P-1037 alone has a greater effect
      on lung function in patients with CF than placebo (0.17% saline).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (number of adverse events of P-1037 in treatment groups)</measure>
    <time_frame>Day 15</time_frame>
    <description>number of adverse events of P-1037 in treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety [change in forced expiratory volume in one second (FEV1) from predosing to 1 hour post dosing]</measure>
    <time_frame>Day 1</time_frame>
    <description>change in FEV1 from predosing to 1 hour post dosing with P-1037 in 4.2 % hypertonic saline and P-1037 in 0.17% saline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in FEV1</measure>
    <time_frame>Day 15</time_frame>
    <description>change in FEV1, from baseline (immediately before first dose) to same time of day on Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of P-1037 on other forced vital capacity (FVC) measures (change in FVC from baseline (immediately before first dose) to same time of day on Day 15)</measure>
    <time_frame>Day 15</time_frame>
    <description>change in FVC from baseline (immediately before first dose) to same time of day on Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of P-1037 on Cystic Fibrosis Questionnaire - Revised (CFQ-R)</measure>
    <time_frame>Day 15</time_frame>
    <description>CFQ-R on Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine whether co-administration of hypertonic saline (HS) enhances the effect of P-1037 on FEV1 (FEV1 on Day 15)</measure>
    <time_frame>Day 15</time_frame>
    <description>FEV1 on Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of P-1037 on (forced expiratory flow at 25%-75% of vital capacity (FEF25-75%)</measure>
    <time_frame>Day 15</time_frame>
    <description>FEF25-75% from baseline (immediately before first dose) to same time of day on Day 15</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>P-1037 in Hypertonic Saline (HS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P-1037 Solution for Inhalation, 85 μg twice daily (BID) (28.3 μg/mL) in hypertonic saline (4.2% saline) BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P-1037 in Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P-1037 Solution for Inhalation, 85 μg BID (28.3 μg/mL) in 0.17% saline BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (0.17% saline) BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertonic Saline</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Hypertonic saline (4.2% saline) BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P-1037</intervention_name>
    <description>P-1037 is a novel ENaC inhibitor</description>
    <arm_group_label>P-1037 in Hypertonic Saline (HS)</arm_group_label>
    <arm_group_label>P-1037 in Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic Saline</intervention_name>
    <description>4.2% saline solution</description>
    <arm_group_label>Hypertonic Saline</arm_group_label>
    <arm_group_label>P-1037 in Hypertonic Saline (HS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>0.17% saline solution</description>
    <arm_group_label>P-1037 in Saline</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 12 years of age or older.

          -  Diagnosis of cystic fibrosis as determined by the 1997 CF Consensus criteria (NIH
             Consensus Statement, 1997)

          -  Non-smoker

          -  FEV1 at Screening Visit 1 between 40% and 90%

          -  Stable regimen of CF medications and chest physiotherapy for the 28 days prior to
             Screening. Must be willing to discontinue use of hypertonic saline for the duration of
             the study.

          -  Clinically stable for at least 2 weeks

          -  All females of child-bearing potential must have a negative serum pregnancy test and
             if sexually active must agree to practice a highly effective form of contraception
             throughout the study and for 28 days after the last dose of study medication.

        Exclusion Criteria:

          -  History of any organ transplantation or any significant disease or disorder

          -  Use of diuretics (including amiloride) or renin-angiotensin antihypertensive drugs or
             trimethoprim in the 28 days prior to Screening

          -  History of significant intolerance to inhaled hypertonic saline, as determined by the
             Investigator

          -  Known hypersensitivity to the study drug or amiloride

          -  Any clinically significant laboratory abnormalities at Screening Visit 1 as judged by
             the investigator, or any of the following:

               -  Potassium ≥ 5 milliequivalent per Liter (mEq/L)

               -  Abnormal renal function

               -  Abnormal liver function, defined as ≥ 3 x upper limit of normal (ULN)

               -  Hemoglobin level &lt; 10.0 g/dL

          -  Female who is pregnant or lactating

          -  History of sputum or throat swab culture yielding Burkholderia species or
             Mycobacterium abscessus within 2 years of screening

          -  Has previously participated in an investigational trial involving administration of
             any investigational compound or use of an investigational device with 28 days prior to
             Screening

          -  Currently being treated with any ivacaftor containing regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Florida Dept of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Adult CF Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary Group, PA</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Lung Associates</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Cystic Fibrosis Institute</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Harper University Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgets-Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Pulmonology/Cystic Fibrosis</name>
      <address>
        <city>Somerville</city>
        <state>New Jersey</state>
        <zip>08876</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santiago Reyes</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anderson Pharmaceutical Research</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Children's Chest Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Clinical Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Texas Health Science Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Childrens</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin UW Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2015</study_first_posted>
  <disposition_first_submitted>May 12, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>May 12, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 15, 2020</disposition_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

